Organogenesis Q2 2026 earnings: Revenue falls 58% as losses widen

Organogenesis Holdings (Nasdaq: ORGO) reported Q2 2026 net product revenue of $42.8 million, down 58% from $100.8 million a year earlier, while diluted GAAP loss per share widened to $(0.77) from $(0.10). A steep decline in Advanced Wound Care revenue and a 28-percentage-point contraction in gross margin outweighed lower selling, general and administrative expenses. Management also reduced its 2026 revenue outlook because the market recovery is progressing more slowly than previously assumed.

Core financial results

Advanced Wound Care accounted for nearly all of the $58.0 million year-over-year decline in quarterly product revenue. Lower revenue was accompanied by significant margin compression, with gross profit falling 74% and operating loss widening by $38.4 million.

The deterioration remained substantial after excluding restructuring, R&D program termination and other specified items: adjusted EBITDA loss increased to $34.4 million from $3.6 million.

Business and segment performance

Advanced Wound Care revenue fell 61% to $36.1 million from $92.7 million, representing $56.6 million of the company’s total $58.0 million product revenue decline. This concentration means the company’s overall recovery remains closely tied to conditions in its largest business.

Surgical & Sports Medicine performed relatively better but still contracted. Revenue declined 18% to $6.7 million from $8.1 million, so it was not large enough to offset the Advanced Wound Care downturn.

Revenue and margin pressure outweighed cost reductions

Cost of goods sold decreased only 14% to $23.7 million while product revenue fell 58%. That mismatch drove gross margin down to 45% from 73% and reduced quarterly gross profit by $54.0 million.

Organogenesis cut selling, general and administrative expenses by 27% to $54.0 million, but R&D expense rose 76% to $18.3 million. Total operating expenses declined 17%, which was not enough to offset the lost gross profit. The quarter also included $5.1 million of restructuring charges and $5.6 million of R&D program termination costs, but the $41.1 million non-GAAP operating loss shows that the pressure extended beyond those adjustments.

The GAAP net loss was also affected by a $45.4 million income tax expense, compared with a $2.4 million tax benefit in the prior-year quarter. Organogenesis reported a $50.9 million pretax loss, but the tax expense pushed its final net loss to $96.3 million. The release did not explain the underlying reason for this tax charge.

Working-capital release limited cash burn, but cash still declined

For the first six months of 2026, net cash used in operating activities improved to $10.5 million from $52.8 million a year earlier despite the much larger net loss. A $119.5 million cash-flow contribution from lower accounts receivable was the main offset to the reported loss and other working-capital outflows.

The cash-flow figures cover the six-month period rather than Q2 alone. Organogenesis also used $4.2 million for capital expenditures and $32.7 million in financing activities, including $19.5 million for construction of landlord assets and $10.2 million of finance lease principal repayments.

Cash, cash equivalents and restricted cash declined to $46.8 million at June 30, 2026, from $94.3 million at December 31, 2025. The company reported no outstanding debt obligations, although its balance sheet separately included finance and operating lease obligations.

Fiscal 2026 guidance

Organogenesis now expects full-year revenue of $179.0 million to $215.0 million. Management still anticipates sequential improvement during the third and fourth quarters, but the expected pace is slower than assumed in its previous outlook.

The most direct indication of the revision is the second-half revenue decline: the new outlook assumes a decrease of approximately 64% to 74%, compared with the prior assumption of a 45% to 52% decline.

Management’s view

CEO Gary S. Gillheeney said business trends showed “measured improvement” during the quarter, but acknowledged that recovery from the significant market contraction was slower than expected. Management believes the company is gaining share as customers focus on evidence and product outcomes, although the release did not provide quantitative market-share data.

Management also continues to advance the ReNu program as a potential route into new markets. Its contribution remains dependent on regulatory approval and successful commercialization.

Recent insider transactions

The supplied transaction-level records list two direct purchases by directors on March 9, 2026. Share quantities and transaction prices were not provided, and a separate six-month aggregate in the source reported zero purchases, creating an inconsistency that investors may want to verify against regulatory filings.

These transactions should be viewed as reported activity only; the disclosed amounts do not establish the insiders’ broader views about the company’s outlook.

Risks investors should monitor

• A slower revenue recovery: The revised second-half assumptions indicate that the market contraction may remain severe through the end of 2026. Further delays would pressure both revenue and operating leverage.
• Dependence on Advanced Wound Care: This segment generated most of the company’s revenue decline, leaving consolidated results highly exposed to its recovery.
• Coverage and reimbursement changes: The company specifically identified CMS’s updated 2026 Medicare reimbursement and coverage changes as a risk to product demand and revenue.
• Margin and liquidity pressure: Gross margin fell sharply, adjusted losses remained substantial and cash declined by $47.5 million during the first half. Continued losses or cash outflows could increase the company’s need to raise funds.
• ReNu execution risk: Future expansion through ReNu depends on obtaining regulatory approval and commercializing the program successfully.

Summary

Organogenesis’ Q2 2026 results reflected a continued contraction in Advanced Wound Care, significant gross-margin pressure and losses that remained large even on an adjusted basis. Cost reductions and improved year-to-date operating cash flow provided some offset, but neither prevented cash from declining materially. The main indicators to follow are the pace of sequential revenue recovery, stabilization in Advanced Wound Care, gross-margin performance and whether results track the reduced full-year guidance.